we know of Harris Pharma and now Akorn Pharma going bankrupt in the US. Perhaps not the honeypot pharma market we are led to believe. Lots of competition. so pleased that Pagais is not a minnow like , DASH, Harris(was) TruPharma. Sure I believe the bigger Pharma Coys will get better licensing terms, but their reach and contacts, current distribution networks that can add extra products to current runs are well worth it IMO. I prefer a shorter priced winner than a long priced loser. I am pleased that overall the announcements are not negative. Jet
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.5¢ |
Change
-0.001(6.25%) |
Mkt cap ! $6.116M | |||
| Open | High | Low | Value | Volume |
| 1.5¢ | 1.5¢ | 1.5¢ | $1.574K | 104.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 609316 | 1.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.6¢ | 438346 | 3 |
View Market Depth
| Last trade - 11.39am 26/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |